Contract Development and Manufacturing Organizations (CDMOs) have long been integral to the pharmaceutical industry, playing a crucial role in outsourcing product research and manufacturing.
Today, CDMOs contribute significantly to the country’s overall pharmaceutical manufacturing, growing at a rate surpassing the total pharmaceutical market’s growth.
The driving factors behind the high growth rate of CDMOs include not only increased outsourcing by pharmaceutical companies but also the escalating demand for specialized services, evolving regulatory landscapes, and advancements in biopharmaceuticals, which propel complex manufacturing needs.
Prominent CDMOs on the international stage include Thermo Fisher Scientific, Lonza Group, Catalent, Patheon, and Recipharm, among others. These organizations offer a comprehensive range of services encompassing drug development, manufacturing, and supply chain solutions for global pharmaceutical and biotechnology companies.
The imperative for pharmaceutical companies to leverage the services of CDMO’s value-added products as there are no longer protracted waiting times for in-house product development, manufacturing, and regulatory approvals.
Marketing professionals within pharmaceutical companies can strategically leverage the services of CDMOs to facilitate the fast-track launch of value-added products, thereby enhancing returns.
CDMOs provide specialized expertise, cost reduction opportunities, accelerated product development, access to advanced technologies, and optimization of resource allocation. This enables pharmaceutical companies to concentrate on their core competencies while concurrently benefiting from the CDMOs’ capabilities in drug development, manufacturing, cost optimisation and regulatory compliance.
433, Shantivan, Near Tarapore Gardens, New Link Road Extension, Andheri West,
Mumbai 400053, India.
